Cargando…
Ropporin-1 and 1B Are Widely Expressed in Human Melanoma and Evoke Strong Humoral Immune Responses
SIMPLE SUMMARY: Despite the unprecedented clinical benefit of immunotherapy in melanoma, some patients still do not respond to treatment, arguing the need for novel therapeutic targets. The aim of this study was to investigate the therapeutic potential of two understudied proteins, Ropporin-1 (ROPN1...
Autores principales: | Da Gama Duarte, Jessica, Woods, Katherine, Quigley, Luke T., Deceneux, Cyril, Tutuka, Candani, Witkowski, Tom, Ostrouska, Simone, Hudson, Chris, Tsao, Simon Chang-Hao, Pasam, Anupama, Dobrovic, Alexander, Blackburn, Jonathan M., Cebon, Jonathan, Behren, Andreas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8069442/ https://www.ncbi.nlm.nih.gov/pubmed/33918976 http://dx.doi.org/10.3390/cancers13081805 |
Ejemplares similares
-
Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmette–Guérin followed by Ipilimumab in Patients with Advanced Metastatic Melanoma
por: Da Gama Duarte, Jessica, et al.
Publicado: (2018) -
PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation
por: Tutuka, Candani S. A., et al.
Publicado: (2017) -
PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma
por: Parakh, Sagun, et al.
Publicado: (2021) -
Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations
por: Chang-Hao Tsao, Simon, et al.
Publicado: (2015) -
Effects of Epithelial to Mesenchymal Transition on T Cell Targeting of Melanoma Cells
por: Woods, Katherine, et al.
Publicado: (2014)